ATEC Alphatec Holdings, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1350653 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.3%
TTM net income YoY43.9%
TTM EPS YoY45.2%
Revenue 3-yr CAGR23.1%
Net income 3-yr CAGR—
Margins
Gross margin71.3%
Operating margin-3.6%
Net margin-10.3%
FCF margin0.4%
EBITDA margin4.7%
Returns
ROE-1,888.0%
ROA-11.0%
ROIC (approx.)-5.4%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets97.3%
Debt / equity—
Current ratio2.36x
Interest coverage-0.65x
Cash quality & payout
Operating cash flow / net income-0.71x
Accruals ratio-18.7%
Payout ratio—
Capex / revenue6.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $764.15M | $611.56M |
| Cost of revenue | $232.27M | $187.30M |
| Gross profit | $531.89M | $424.26M |
| R&D expense | $76.27M | $80.72M |
| SG&A expense | $498.53M | $450.20M |
| Operating income | -$82.13M | -$136.17M |
| Interest expense | $45.92M | $24.88M |
| Pretax income | -$143.40M | -$162.07M |
| Income tax | -$45,000 | $50,000 |
| Net income | -$143.36M | -$162.12M |
| EBITDA | -$4.64M | -$57.75M |
| EPS (basic) | -0.96 | -1.13 |
| EPS (diluted) | -0.96 | -1.13 |
| Weighted avg. shares (diluted) | 150.06M | 142.95M |
| Balance sheet | ||
| Cash & equivalents | $160.81M | $138.84M |
| Receivables | $97.30M | $82.99M |
| Inventory | $169.44M | $175.26M |
| Current assets | $450.88M | $417.40M |
| PP&E, net | $135.32M | $156.39M |
| Goodwill | $75.21M | $70.98M |
| Intangibles | $93.45M | $93.52M |
| Total assets | $791.21M | $775.71M |
| Current liabilities | $219.18M | $153.03M |
| Short-term debt | $64.53M | $1.66M |
| Long-term debt | $501.41M | $574.52M |
| Total debt | $565.94M | $576.18M |
| Total liabilities | $755.18M | $766.28M |
| Shareholders' equity | $12.43M | -$14.17M |
| Net debt | $405.13M | $437.34M |
| Shares outstanding | 150.26M | 144.13M |
| Cash flow statement | ||
| Operating cash flow | $45.23M | -$44.65M |
| Capital expenditure | $42.45M | $83.22M |
| Free cash flow | $2.78M | -$127.87M |
| Investing cash flow | -$53.41M | -$93.14M |
| Financing cash flow | $30.02M | $56.21M |
| Depreciation & amortization | $77.49M | $78.42M |
| Stock-based compensation | $73.72M | $73.28M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.